|
 |
RifamycinThis page contains recent news articles, when available, and an overview of Rifamycin but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.The company said it has proposed two international multicenter, randomized, double-blind studies of rifamycin SV MMX, a broad spectrum, semi-synthetic ... RTT News Santarus seeks US FDA nod to begin phase III trial of rifamycin SV MMX in ... - Jan 3, 2010 Santarus has licensed exclusive rights to develop and commercialize rifamycin SV MMX in the US from Cosmo Technologies Limited, a wholly owned subsidiary of ... pharmabiz.com Stocks in the News: Pfizer, Nokia, Apple - Dec 30, 2009 Santarus Inc. (SNTS) submitted an investigational new-drug application to the FDA, seeking to begin a Phase III evaluation of rifamycin SV MMX to treat ... Daily Finance Benzinga's News Roundup (SNTS, MRVL, NVO, AET, CIEN, NVDA) - Dec 30, 2009 ...to the US Food and Drug Administration (FDA) to begin a Phase III clinical program evaluating rifamycin SV MMX in patients with travelers` diarrhea. ... Benzinga 91X, Magic 92.5 and Z90 radio stations up for sale - Dec 31, 2009 ...sized study to start in the first half of 2011. Patients will take the drug, rifamycin, twice a day for three days, with results compared against a placebo. San Diego Union Tribune News and FDA Updates for Origin Agritech (NASDAQ:SEED), Rite Aid (NYSE:RAD ... - Dec 31, 2009 ...and Drug Administration (FDA) requesting approval to begin a Phase III clinical program evaluating rifamycin SV MMX® in patients with travelers´ diarrhea. American Chronicle Wednesday's biggest gaining and declining stocks - Dec 30, 2009 Santarus licenses the rights to develop and commercialize rifamycin SV MMX in the US from a subsidiary of Cosmo Technologies SpA. Trico Marine Services Inc. ... Middle East North Africa Financial Network Santarus Announces Webcast Presentation at the Lippert/Heilshorn Life Sciences ... - Dec 14, 2009 Santarus is also developing two late-stage lower GI product candidates, budesonide MMX ® and rifamycin SV MMX ® , for the US market. ... Behavioral Health Central (blog) Budesonide European Trial Enrolled - Analyst Blog - Dec 10, 2009 In addition to in-licensing budesonide MMX from Cosmo in December 2008, Santarus in-licensed another late stage pipeline candidate from Cosmo − rifamycin ... Benzinga Santarus Receives Previously Announced $20 Million Milestone for FDA Approval ... - Dec 22, 2009 Rifamycin SV MMX has been investigated in a Phase II clinical program in travelers' diarrhea. More information about Santarus is available on the company's ... FOXBusiness Sign Up For Our Free Newsletter!! AGRT,ACTG,ZAGG,SNTS,CTIC,BLDP - Dec 22, 2009 Rifamycin SV MMX has been investigated in a Phase II clinical program in travelers' diarrhea. More information about Santarus is available on the company's ... TMC Net Santarus 申请开始第三阶段实验 - Dec 30, 2009 Santarusæ??议进行两项国际多ä¸å¿ƒä¸¶éš?选丶å?Œç›²å®žéªŒï¼Œçº¦æ‹›å‹Ÿ300å??病患，评估rifamycin SV MMX 400 mg疗效与安全。 å…?è´£å£°æ˜Žï¼šæœ¬æ–‡ä»…ä»£è¡¨ä½œè€…ä¸ªäººè§‚ç‚¹ï¼Œä¸Žå‡¤å‡°ç½‘æ— å…³ã€‚ ... 凤凰网 PRESSE/Cosmo-CFO ab 2012 jährliches Umsatzwachstum von 50 Mio CHF - Dec 17, 2009 Dazu kämen die Phase III-Medikamente Budesonide und Rifamycin. Das Risiko, dass die Cosmo-Projekte scheiterten, sei kleiner als bei Biotech-Unternehmen, ... Handelszeitung Online PRESSE/Cosmo: hausse des ventes de 50 mio CHF par an à partir de 2012 (CFO) - Dec 17, 2009 Les médicaments Budesonide et Rifamycin sont par ailleurs en phase III. Le risque d'un échec est moindre que pour les produits biotechnologiques, ... Romandie.com Santarus Inc. Q3 2009 Earnings Call Transcript - Nov 4, 2009 Turning to Rifamycin SV MMX we continue on track to file an investigational new drug application for Rifamycin SV MMX and initiate a phase III clinical ... Seeking Alpha (blog) Santarus to Present at Lazard Capital Markets 6th Annual Healthcare Conference - Nov 10, 2009 Rifamycin SV MMX has been investigated in a Phase II clinical program in travelers' diarrhea. More information about Santarus is available on the company's ... WELT ONLINE Positive Data from Two Investigator-Initiated Studies with Santarus` ZEGERID ... - Oct 26, 2009 Rifamycin SV MMX has been investigated in a Phase II clinical program in travelers` diarrhea. More information about Santarus is available on the company`s ... Reuters Santarus Reports Strong Quarter - Nov 9, 2009 Long-term, we like the position of the company, especially if Santarus can hold on to Zegerid until budesonide or rifamycin, or both, gets on the market. Zacks.com Santarus Ranked Number 23 Fastest Growing Company in North America on ... - Oct 20, 2009 Rifamycin SV MMX has been investigated in a Phase II clinical program in travelers' diarrhea. More information about Santarus is available on the company's ... Trading Markets (press release) Cosmo's Rifamycin meets target in diarrhoea trial - Jul 4, 2007 ZURICH, July 4 (Reuters) - Italy's Cosmo Pharmaceuticals (COPN.S) said on Wednesday a mid- to late-stage trial of its Rifamycin drug in infectious diarrhoea ... Reuters Acquired Rifamycin Resistance With Twice-Weekly Treatment of HIV- … - Feb 9, 2006 Rationale: Rifabutin was recommended in place of rifampin during treatment of HIV-related tuberculosis (TB) to facilitate concomitant potent antiretroviral ... RedOrbit Rifamycin MMX impresses at Ph II/III. - Jul 16, 2007 Phase II/III data from a trial of Italian drugmaker Cosmo Pharmaceuticals' broad-spectrum antibiotic Rifamycin MMX (CB-01-11) indicate that the drug is ... Free with registration - Pharma Marketletter - AccessMyLibrary.com … with Cosmo for US Rights to Budesonide MMX® and Rifamycin SV MMX … - Dec 15, 2008 Rifamycin SV MMX is a broad spectrum, semi-synthetic antibiotic that also ... The application of MMX technology to Rifamycin SV allows the antibiotic to be ... International Business Times When the waiting proves fatal - Jun 16, 2005 Nevirapine — one of the drugs given as part of ART — and Rifamycin given for ... This leads to Rifamycin increasing the metabolism of Nevirapine and in turn ... The Hindu … for US Rights to Budesonide MMX and Rifamycin SV MMX | Article... - Dec 19, 2008 Rifamycin SV MMX is a broad spectrum, semi-synthetic antibiotic that also ... The application of MMX technology to Rifamycin SV allows the antibiotic to be ... Pay-Per-View - Wireless News - HighBeam Research Drug Resistance; Acquired rifamycin resistance risk increases with... - Mar 28, 2006 2006 MAR 28 - (NewsRx.com) -- Risk of acquired rifamycin resistance is high in patients on twice-weekly treatment for HIV-related tuberculosis. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Cosmo Pharmaceuticals Reports Rifamycin Phase II/III Data - Jul 9, 2007 Italian drug company Cosmo Pharmaceuticals announced positive preliminary results from its Phase II/III study with Rifamycin in infectious diarrhea. ... FDA news - FDA news (subscription) Rifamycin Meets Endpoints in Diarrhea Trial - Dec 3, 2007 Italian drugmaker Cosmo Pharmaceuticals' Rifamycin SV MMX achieved its endpoint of noninferiority versus Normix in a Phase II trial for the treatment of ... FDA news - FDA news (subscription) … Pharmaceuticals to launch phase III trails on diarrhoea drug Rifamy... - Nov 29, 2007 ZURICH (Thomson Financial) - Cosmo Pharmaceuticals SpA said it is preparing phase III trails for its treatment for infectious diarrhoea, Rifamycin SV MMX, ... ABCmoney.co.uk … Development Strategy for Its Novel Rifamycin Antibiotics. - PR... - Feb 25, 2008 ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Treatment Outcomes of Patients with HIV and Tuberculosis - Jun 1, 2007 HIV-infected patients who received 6 months of rifamycin-based TB treatment or who were treated intermittently (one to three times per week), ... DG News Cosmo's Rifamycin non-inferior to Normix in Ph II study.(Clinical... - Dec 10, 2007 Italy-based Cosmo Pharmaceuticals SpA says that its broad-spectrum antibiotic Rifamycin SV MMX (CB-01-11) has demonstrated non-inferiority to the comparator ... $4.95 - Pharma Marketletter - ECNext Guidelines Updated on Managing Drug Interactions With HIV-Related TB - Feb 6, 2008 The pharmacokinetic effect of rifamycin is modest and well-characterized, ... The pharmacokinetic effect of the rifamycin is moderate in this regimen. ... Medscape Press Release: ActivBiotics Inc. Presentation at the 45th Interscience... - Dec 20, 2005 Through its medicinal chemistry program focusing on novel rifamycin antibiotics, the Company recently nominated a new drug ... Company's lead pre-clinical ... Pay-Per-View - PR Newswire - HighBeam Research X-Ray - Your Guide to All the Key X-Ray Techniques - Sep 12, 2005 Their data on two representatives of each class of rifamycin - rifapentin and rifabutin - reveal that these drugs, remove a key component of bacteria - the ... spectroscopyNOW.com Researchers find how some antibiotics kill bacteria - Dec 8, 2005 The antibiotics studied belong to the rifamycin family. Until now, researchers believed that these antibiotics and their derivatives (there are at least a ... innovations report - Innovations-Report Johns Hopkins University, US Recent research focus of reports from … - Dec 12, 2006 Investigators concluded, "By virtue of the enhanced rifamycin exposure, twice-weekly regimens containing rifapentine (15 or 20 mg/kg) may permit shortening ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Drug-induced acute cholestatic liver damage in a patient with... - Aug 17, 2006 Liver damage can also occur because of an increased drug concentration in the tissue where excretion/detoxification takes place (eg rifamycin). ... Nature.com Drug Resistance; Researchers find how some antibiotics kill bacteria - Sep 2, 2005 The antibiotics studied belong to the rifamycin family. Until now, researchers believed that these antibiotics and their derivatives (there are at least a ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Ohio State University; Researchers find how some antibiotics kill... - Aug 31, 2005 The antibiotics studied belong to the rifamycin family. Until now, researchers believed that these antibiotics and their derivatives (there are at least a ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones Drug-Resistant TB May Respond to Aggressive Treatment - Aug 25, 2008 In patients who received self-administered therapy or a non-rifamycin regimen and who have a relapse, the risk of acquired drug resistance is substantial. ... Insidermedicine ActivBiotics updates product pipeline at ICAAC.(Interscience Conferenc... - Jan 9, 2006 Massachusettes, USA-based ActivBiotics' lead product candidate rifalazil, and several of its development pipeline rifamycin-based compounds, ... Free with registration - Pharma Marketletter - AccessMyLibrary.com XDR-TB Rate Holding Steady After Decline - Nov 14, 2008 All told, there were 212896 reported TB cases and 95% of them had drug susceptibility results reported for isoniazid (Nydrazid) and a rifamycin, ... MedPage Today Shorter, simpler TB regimen considered a priority.(Infectious... - Aug 1, 2006 Treatment of TB patients coinfected with HIV--a large and growing population--is essentially the same, with the added complication that rifamycin and ... Free with registration - Family Practice News - AccessMyLibrary.com Rifampicin resistance linked to dosing schedule in HIV-positive TB … - Jun 13, 2005 Both drugs are members of the rifamycin class of antibiotic drugs, and taking either drug can lead to rifampicin resistance. ... Aidsmap Tuberculosis therapy in HIV-infected patients - Jun 3, 2007 HIV-infected patients who received 6 months of rifamycin-based TB treatment or who were treated intermittently (one to three times per week), ... News-Medical.net Factiva Search - Apr 26, 2006 Drug Development; Rifamycin-resistant Staphylococcus aureus susceptible to novel rifamycins. 26 April, 2006 Life Science Weekly ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Treatment Outcomes of Patients with HIV and Tuberculosis - May 30, 2007 HIV-infected patients who received 6 months of rifamycin-based TB treatment or who were treated intermittently (one to three times per week), ... newswise.com Study offers insight on antibiotics - Aug 12, 2005 The antibiotics studied belong to the rifamycin family. Until now, researchers believed that these antibiotics and their derivatives, of which there are at ... Pay-Per-View - Datamonitor News and Comment - Factiva, from Dow Jones Treatment Outcomes Of Patients With HIV And Tuberculosis - Jun 7, 2007 HIV-infected patients who received 6 months of rifamycin-based TB treatment or who were treated intermittently (one to three times per week), ... Medical News Today - Medical News Today (press release) LIVESTOCK: Chance to learn more about sheep diseases. - May 11, 2007 Other work suggested oxytetracylcline and rifamycin - a drug used in the ... Rifamycin was not approved for animal use and a major problem was that ... Free with registration - Farmers Guardian - AccessMyLibrary.com Cosmo bleibt in den roten Zahlen - Jul 30, 2008 Cosmo erwarte, im zweiten Halbjahr 2008 einen Lizenzvertrag für Europa für Rifamycin SV MMX, einer Tablette zur Behandlung von infektiöser Diarrhö, ... Moneycab.com Alcoholic Liver Disease Encephalopathy - Alcoholic Liver Disease... - Dec 12, 2008 Antibiotics, such as metronidazole, rifamycin, or neomycin, are effective in reducing levels of ammonia-producing bacteria in the intestine, ... New York Times Tuberculosis, a neglected opportunity? - Nov 2, 2006 The five mainstay TB treatments—rifampicin (also referred to as rifamycin), isoniazid, pyrazinamide, ethambutol and streptomycin—were introduced between ... Nature.com Where have all the antibiotic patents gone? - Oct 23, 2006 These include erythromycin, vancomycin, rifamycin, clarithromycin, ciprofloxacin and azithromycin. The vast majority of patents related to antibiotics are ... Nature.com Computer Simulation: Monte Carlo races - May 19, 2005 When the team interfered with one of the enzymes involved in this process, Escherichia coli did not evolve resistance to important quinolone and rifamycin ... Nature.com Is rifampin a safe and effective treatment for pruritus caused by... - Oct 20, 2006 Keywords including rifampin, rifampicin, rifamycin, pruritus, cholestasis, itching and liver disease were used. Trials that prospectively compared the use ... Nature.com Santarus与Cosmoç¾ç½²ç–ç•¥å?ˆä½œå??è®® - Dec 15, 2008 Pharmaceuticals SpA旗下å?å…¬å?¸Cosmo Technologiesç¾ç½²ç–ç•¥å?ˆä½œå??议，对Santarus 授与美国地区独家开å?‘与商业行销Budesonide MMX与Rifamycin SV MMXçš„æ?ƒåˆ©ã€‚ ... 凤凰网 Family Struggles to Find Burial Place for Milosevic - Mar 14, 2006 Dr. PETER DE SMET (Dutch Pharmaceutical Association): One of the effects that rifamycin (ph) has is that it stimulates the enzymes in the liver and these ... $3.95 - National Public Radio - NewsBank To create awareness - Mar 25, 2007 The DTCS also conducted a camp in Tuticorin to inform pharmacists on the correct dosage of rifamycin, ethambutol and pyrazinamide to be administered to ... The Hindu Therapeutic treasures from the deep - Jul 1, 2007 Members of related genera of soil-dwelling actinomycetes make other precious antibiotics: erythromycin, gentamicin, rifamycin and vancomycin. ... Nature.com GI Journal Scan May 2005 - May 17, 2005 This current study by DuPont and colleagues involved the use of rifaximin -- a nonabsorbable rifamycin analogue antibiotic -- for the prophylaxis of ... Medscape Cases of extensively drug-resistant TB declining each year in the US,... - Nov 11, 2008 XDR-TB was defined as resistance to isoniazid, a rifamycin, a fluoroquinolone, and at least one of amikacin, kanamycin, or capreomycin based on drug ... PhysOrg.com New Antibiotic Candidates From Braunschweig (Germany) - Oct 18, 2008 The novel target is different from the target of known antibiotics such as rifamycin, a standard medication to counteract tuberculosis. ... Medical News Today - Medical News Today (press release) Antibiotic Aims at IBS Bloating and Global Symptoms - Oct 19, 2006 Xifaxan is a gut-selective antibiotic derived from the rifamycin family that may reduce bacterial overgrowth due to its broad-spectrum activity in vitro ... MedPage Today ActivBiotics Announces Expansion of Phase-3 PROVIDENCE-1 Study of … - Nov 14, 2005 In addition, the Company has a library of over 1500 development candidates in the same antibacterial family as rifalazil, the rifamycin family. ... RedOrbit Cases Of Extensively Drug-resistant TB Declining Each Year In The US,... - Nov 21, 2008 XDR-TB was defined as resistance to isoniazid, a rifamycin, a fluoroquinolone, and at least one of amikacin, kanamycin, or capreomycin based on drug ... sciencedaily.com Use of Therapeutic Drug Monitoring in Tuberculosis Patients - Jan 7, 2005 Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycinbased regimens. ... RedOrbit Update on tuberculosis -- 2005 - Mar 1, 2006 He noted that an alternate member of the rifamycin class called rifabutin has much less effect against the antiretroviral agents. ... eurekalert.org Urogenital tuberculosis in a patient with AIDS: an unusual presentatio... - Aug 20, 2007 2 Despite this drug interaction, however, a rifamycin should be included in tuberculosis treatment for patients receiving antiretroviral therapy, ... Nature.com A Reduction In Tuberculosis Incidence, Prevalence And Death Rate Can ... - Mar 4, 2006 He noted that an alternate member of the rifamycin class called rifabutin has much less effect against the antiretroviral agents. ... Medical News Today - Medical News Today (press release) Article: University of Illinois at Chicago Developing Drug for SARS. ... - Jun 8, 2005 For some HIV ... the Centers for Disease Control and Prevention ... interactions between protease inhibitors and the rifamycin ... ... Pay-Per-View - Ascribe Higher Education News Service - HighBeam Research Press Release: Mersana Therapeutics, Inc. Appoints John H. van Duzer,... - Jan 16, 2008 As a Vice President of Manufacturing at ActivBiotics, he led efforts for the development of a liquid dosage form of a rifamycin, an oral antibacterial agent ... Pay-Per-View - PR Newswire - HighBeam Research Salix Pharmaceuticals: Xifaxan potential lies in label extensions - Jan 26, 2007 Xifaxan is an orally administered rifamycin antibacterial that is poorly absorbed by the gastrointestinal (GI) tract, thereby acting as a topical antibiotic ... Pharmaceutical Business Review Efficacy of Rifaximin vs Placebo in Reducing Symptoms in Adults With... - Nov 10, 2006 Rifaximin is a nonabsorbable, gut-selective antibiotic derived from the rifamycin family that may reduce bacterial overgrowth due to its broad-spectrum ... Medscape Resisting the call for new antibacterials? - Apr 30, 2007 CBR-2092, which comprises of a rifamycin unit linked to a flouroquinolone unit via a stable linker, is currently in Phase I trials. DrugResearcher.com Shorter, simpler TB regimen considered a priority.(Infectious... - Aug 15, 2006 Both fluoroquinolones have pharmacokinetics amenable to weekly dosing, as does rifapentine, a long-acting rifamycin developed in the 1990s. ... Free with registration - Internal Medicine News - AccessMyLibrary.com Rifampicin, isoniazid and ethambutol hydrochloride tablets.(Internatio... - Jun 22, 2007 25 minutes): 3-(isonicotinoylhydrazinomethyl)rifamycin [the "hydrazone" resulting from reaction between 3-formylrifamycin and isoniazid] about 0.5; ... Free with registration - WHO Drug Information - AccessMyLibrary.com CDAD: Novel Therapeutics - Oct 1, 2006 A number of additional agents are being investigated for treatment of CDAD, including the lipoglycodepsipeptide, ramoplanin, the rifamycin, rifaximin, ... Free with registration - Infectious Disease Alert - AccessMyLibrary.com Press Release: ActivBiotics' Intellectual Property Assets, Including... - Apr 2, 2008 The assets consisted of 1) Rifalazil, a Phase II antibiotic, 2) a library of novel rifamycin compounds, and 3) a clinical stage superoxide dismutase mimetic ... Pay-Per-View - PR Newswire - HighBeam Research Contamination risk increases from multiple bacterial strains. - Apr 1, 2005 Scott-A Str was developed with resistance to streptomycin, while OSY-8578 Rf,Nm was made resistant to both rifamycin b and neomycin. ... $4.95 - Microbial Update International - ECNext Virginia Regulations - 12 VAC 5-90-225. Additional data to be... - Aug 9, 2005 ...(2) Known or suspected active TB disease resistant to rifampin, rifabutin, rifapentine or other rifamycin with or without resistance to any other drug. ... Pay-Per-View - Virginia Regulations - Loislaw Prelog, Vladimir -- Britannica Online Encyclopedia - Jun 16, 2008 His work with steroids, antibiotics, and antimicrobial chemical structures, including nonactins and rifamycin, facilitated a variety of pharmaceutical ... Subscription - Encyclopedia Britannica Antimicrobial Resistance; MutS fusion proteins as recognition... - Dec 5, 2005 ...and unpaired mutations in the synthesized oligonucleotides and single base mutation in rpoB gene of M. tuberculosis that is resistant to rifamycin." ... Pay-Per-View - Anti-Infectives Week - Factiva, from Dow Jones Contamination risk increases from multiple bacterial strains. |... - Apr 1, 2005 Scott-A Str was developed with resistance to streptomycin, while OSY-8578 Rf,Nm was made resistant to both rifamycin b and neomycin. ... Pay-Per-View - Microbial Update International - HighBeam Research Press Release: ActivBiotics Announces Expansion of Phase-3 … - Nov 14, 2005 In addition, the Company has a library of over 1500 development candidates in the same antibacterial family as rifalazil, the rifamycin family. ... Pay-Per-View - PR Newswire - HighBeam Research ActivBiotics, Inc. to Sponsor Satellite Symposium at 2006 ACC Meeting. - Mar 10, 2006 Based on its experience with rifalazil, the Company has amassed a library of over 1500 biologically active compounds from the rifamycin class of antibiotics ... $4.95 - PR Newswire - ECNext Press Release: ActivBiotics, Inc. to Sponsor Satellite Symposium at... - Mar 10, 2006 Based on its experience with rifalazil, the Company has amassed a library of over 1500 biologically active compounds from the rifamycin class of antibiotics ... Pay-Per-View - PR Newswire - HighBeam Research Antimicrobial Resistance; MutS fusion proteins as recognition... - Dec 11, 2005 ...and unpaired mutations in the synthesized oligonucleotides and single base mutation in rpoB gene of M. tuberculosis that is resistant to rifamycin." ... Pay-Per-View - Medical Devices & Surgical Technology... - Factiva, from Dow Jones Extending higher dosage of etanercept found safe: some prescribers... - Nov 1, 2005 Patients were then randomized ... plus 600 mg rifamycin twice weekly or 900 mg isoniazid ... of follow-up, 48 patients in the rifapentine group ... about ... Pay-Per-View - Family Practice News - HighBeam Research ActivBiotics, Inc. Appoints Glenn Kazo to Senior Management Team as … - Jan 10, 2005 Through its medicinal chemistry program focusing on novel rifamycin antibiotics, the Company recently nominated a new drug candidate, ABI-0043, ... $4.95 - PR Newswire - ECNext Chinese Academy of Sciences, Beijing; MutS fusion proteins as … - Dec 7, 2005 ...and unpaired mutations in the synthesized oligonucleotides and single base mutation in rpoB gene of M. tuberculosis that is resistant to rifamycin." ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones rifaximin Salix initiates clinical trial for the prophylaxis of... - Jul 18, 2005 ...the prevention of travelers' diarrhea is expected to begin in Asia second half 2005. ....Rifaximin, an oral semisynthetic derivative of rifamycin, has been. Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Antimicrobial Resistance; MutS fusion proteins as recognition... - Dec 9, 2005 ...and unpaired mutations in the synthesized oligonucleotides and single base mutation in rpoB gene of M. tuberculosis that is resistant to rifamycin." ... Pay-Per-View - Genomics & Genetics Weekly - Factiva, from Dow Jones Article: Research Leads to First Treatment for Drug-Resistant HIV. - ... - Aug 2, 2006 However, these protease inhibitors interact with rifamycin derivatives ... Rifamycins accelerate the metabolism of protease inhibitors (through induction of ... Pay-Per-View - AScribe Medicine News Service - HighBeam Research Antimicrobial Resistance; MutS fusion proteins as recognition... - Dec 5, 2005 ...and unpaired mutations in the synthesized oligonucleotides and single base mutation in rpoB gene of M. tuberculosis that is resistant to rifamycin." ... Pay-Per-View - Proteomics Weekly - Factiva, from Dow Jones Article: Rifaximin-loperamide combination knocks out traveler's... - Jul 15, 2006 Rifaximin is a rifamycin derivative that is being ... submitted a New Drug Application (NDA) for rifaximin for the treatment of travelers' diarrhea ... ... Pay-Per-View - Internal Medicine News - HighBeam Research Cumbre Announces New Financing. - Oct 9, 2007 CBR-2092 is Cumbre's most advanced multifunctional drug candidate and is a novel rifamycin-quinolone hybrid antibiotic that was optimized for its activity ... $4.95 - PR Newswire - ECNext rifaximin Altana, Salix licensing agreement.(Pharmaceutical industry)(... - Mar 14, 2005 Rifaximin, a semisynthetic derivative of rifamycin was launched in the USA in 2004 as an oral antibiotic for the treatment of traveler's diarrhea caused by ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Management of active tuberculosis.(Disease/Disorder overview)(Cover … - Dec 1, 2005 Several potential drug interactions are associated with the medications used for treatment of tuberculosis, most notably, the rifamycin drugs. ... $4.95 - American Family Physician - ECNext Cosmo's 1st-half loss up 325% on R&D costs. - Aug 13, 2007 The firm said the shortfall was due to a 54% increase in drug development costs, citing the Phase II/III trials of its broad spectrum antibiotic Rifamycin ... $9.94 - Pharma Marketletter - Alacra Store Arizona Administrative Code - R9-6-205. Reporting Requirements for a ... - Aug 12, 2005 Any rifamycin, 4. Pyrazinamide, or 5. Ethambutol. C. A pharmacist or an administrator of a pharmacy shall submit a report required under subsection (A) by ... Pay-Per-View - Arizona Administrative Code - Loislaw ActivBiotics Inc. Presentation at the 45th Interscience Conference on... - Dec 20, 2005 20 /PRNewswire/ -- ActivBiotics, Inc.'s lead product candidate, rifalazil, and pipeline of novel rifamycin compounds were the subject of eleven ... $4.95 - PR Newswire - ECNext Article: Tennis: Wimbledon 2005: ORDER OF PLAY.(Sport) - Daily Post (... - Jun 22, 2005 USA-based Santarus has licensed Cosmo Pharmaceuticals SpA's two drugs Budesonide MMX and Rifamycin SV MMX for its domestic market. ... Pay-Per-View - Daily Post - HighBeam Research Mycobacterium abscessus and other nontuberculous mycobacteria: … - Jun 1, 2005 ATS consensus statement recommended empiric treatment with daily azithromycin or clarithromycin, ethambutol, and a rifamycin (rifampin or rifabutin). ... $4.95 - Southern Medical Journal - ECNext Helmholtz-Zentrum für Infektionsforschung Neue Antibiotika-Kandidaten... - Oct 17, 2008 ...den Bakterien an einer anderen Stelle wirken als alle bisher bekannten Antibiotika - wie etwa das Rifamycin, ein Standardmedikament gegen Tuberkulose. ... pressrelations.de Inhibitory and Inductive Effects of Rifampin on the Pharmacokinetics... - Oct 4, 2006 Vavricka, SR, Van Montfoort, J., Ha, HR, Meier, PJ & Fattinger, K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human ... Nature.com Thuốc trị viêm tai - Coi chừng Ä‘iếc - Nov 3, 2008 Rifamycin gây tác Ä‘á»™ng trên các ARN polymerase phụ thuá»™c AND bằng cách hình thà nh má»™t phức hợp ổn định gây ức chế sá»± tăng trưởng của vi khuẩn. ... Tin nhanh RNA 중합효소 스위치 ì˜?ì—ì—? 결합·불능화 - Oct 20, 2008 ...있는 가운ë?° 다른 ë°©ì‹?으로 작용함으로ì?¨, '리파마ì?´ì‹ '(rifamycin) 등ì—? ì €í•ì?´ ìƒ?긴 결핵 ë°? ê°?종 박테리아를 효과ì ?으로 ë°•ë©¸í• ìˆ˜ 있ì?„ 것ì?´ë?¼ê³ 기대했다. ... 디지틀보사 Cosmo Pharmaceuticals "hold" - Dec 15, 2008 Cosmo habe heute Morgen bekannt gegeben, dass es in den USA einen Partner für Budesonid MMX und Rifamycin MMX gefunden habe. ... AktienCheck Quelle: Christine Case/Skyline College California - Oct 22, 2008 ...den Bakterien an einer anderen Stelle wirken als alle bisher bekannten Antibiotika - wie etwa das Rifamycin, ein Standardmedikament gegen Tuberkulose. ... biotechnologie.de Farmaceutica, italiana Cosmo prevede nuova licenza entro anno - Sep 24, 2008 ...raggiungere quest'anno un accordo di licenza per l'Europa per l'antibiotico contro le infezioni intestinali Rifamycin ed ha già individuato un partner. ... Milano Finanza Impact of the components of metabolic syndrome on oxidative stress... - Jul 21, 2006 The role of 8-hydroxy-2'-deoxyguanosine in rifamycin-induced DNA damage. Free Radic Biol Med 1995; 18: 747–755. | Article | PubMed |. Bland JM, Altmann DG. ... Nature.com A Randomized Double-Blind Placebo-Controlled Trial of Rifaximin in … - Mar 14, 2005 Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis 1993;16: 111–118. Gillis, JC, Brogden, RN. ... Nature.com Updated Guidelines on Managing Drug Interactions in the Treatment of ... - Feb 1, 2008 Article: Acquired rifamycin resistance in persons with advanced HIV ... Morbidity and Mortality Weekly Report; March 15, 2002 ; 700+ words ... ... for ... Pay-Per-View - MMWR. Morbidity and Mortality Weekly... - HighBeam Research |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |